August 1, 2005 The Centient Biotech 200 cruised through its old high of 3760 today, climbing almost 48 points to end at 3782.84, a rise of 1.28%, substantially above the 3760 mark that has stood since April of 2004. Isolagen got cut in half after it met just 3 out of 4 endpoints in a Phase III trial of a dermatology process that treats contour deformities, Amgen and Abgenix won fast-track status for their colorectal cancer drug, Human Genome Science received a $7 million milestone from Glaxo, Discovery Labs responded to the FDA concerns about Surfaxin, Pfizer added on an indication for Celebrex, Teva increased Q2 profits, Ivax came in a little light, Watson won approval for two generic contraceptives, and the FDA allowed Guidant to put it Contak Renewal 3 defibrillators back on the market. More details...
